... that last several months, not just days, was always Dexcom's focus, but once they noticed the 2 competitors bringing few-day type products to market they realized it would be easy to jump in that niche. They developed the few-day product in around 2 years, and at relatively little cost. Meanwhile, Abbott still lacks FDA approval-- my guess is that is because of a history that lacks at least some integrity
The poll doesn't describe the system, need for calibration 2-4 x per day, problems with moisture (that would interfere with bathing), and other drawbacks and limitations. Additionally, the online poll is selects a biased respondent pool. I wouldn't read too much into this. DXCM's market cap is in the statosphere and hugely overestimates the number of systems that will actually be sold.